Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®) - LUPRA
- Conditions
- Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP.MedDRA version: 8.1Level: LLTClassification code 10015902Term: Exudative senile macular degeneration of retina
- Registration Number
- EUCTR2006-004367-57-AT
- Lead Sponsor
- Department of Ophthalmology, Medical University of Graz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15
Patients who at baseline
•have a best corrected visual acuity (BCVA) letter score in the study eye between 73-24 (approximately 20/40 to 20/320) using an ETDRS chart measured at 4 meters or Snellen equivalent
•have a RAP lesion in the study eye with the following characteristics as determined by fluorescein and indocyanine green angiography:
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•any other form of AMD or of neovascular maculopathy, including pathologic myopia, angioid streaks, infectious or inflammatory chorioretinal diseases, ocular tumors, prior radiation therapy, hereditary disorders, or trauma.
•Patients who have a BCVA of < 33 letters (approximately 20/200) in both eyes
•Prior treatment in the study eye with verteporfin, external-beam radiation therapy, vitrectomy, submacular surgery, other surgical intervention for AMD, or transpupillary thermotherapy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method